Posted by Michael Wonder on 07 May 2020
The equitable distribution of COVID-19 therapeutics and vaccines
7 May 2020 - Scientists from across the globe are racing to develop effective vaccines and therapeutics for COVID-19.
On March 16, phase 1 clinical trials started with a vaccine candidate developed by a US-based company, supported by the National Institutes of Health and the Coalition of Epidemic Preparedness Innovations (CEPI).
The next day, a Chinese biotechnology firm announced government authorization to begin clinical trials. Eight vaccine candidates are in clinical trials and more than 100 more are in preclinical development in more than 12 countries. Dozens of therapeutics are also in pre-clinical and clinical development.
